论文部分内容阅读
因子Ⅹa选择性抑制剂戊聚糖钠是新一代抗栓药物 ,对抗凝血酶Ⅲ有选择性高亲和力 ,特异性催化因子Ⅹa失活 ,产生无因子Ⅱa抑制或抗血小板活性的抗凝血酶作用 ,从而显著降低静脉血栓栓塞的危险性。在预防大型矫形手术后静脉血栓栓塞时 ,戊聚糖钠皮下用药最佳剂量为 1 .5～ 3mg ,每日一次给药 ,具有较好的耐受性 ,在推荐临床剂量 2 .5mg时 ,与标准药物依诺肝素一样具有类似的耐受性 ,但戊聚糖钠不会产生抗体诱导血小板减少的副作用
Factor Xa selective inhibitor sodium pentosan is a new generation of antithrombotic drugs, selective high affinity for antithrombin Ⅲ, the specific catalytic factor Xa inactivation, no factor Ⅱ a inhibition or anti-platelet activity of antithrombin effect , Thereby significantly reducing the risk of venous thromboembolism. In the prevention of large-scale orthopedic surgery after venous thromboembolism, pentosal sodium subcutaneous administration of the best dose of 1.5 ~ 3mg, once daily administration, has better tolerability, the recommended clinical dose of 2.5mg, Similar to standard drug enoxaparin, pentosan did not produce the side effects of antibody-induced thrombocytopenia